These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29577765)

  • 21. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
    Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA
    HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
    Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
    J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
    Butt AA; Yan P; Shuaib A; Abou-Samra AB; Shaikh OS; Freiberg MS
    Gastroenterology; 2019 Mar; 156(4):987-996.e8. PubMed ID: 30445009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
    Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
    Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy.
    Kuo MH; Tseng CW; Lee CH; Yang YC; Wu HJ; Lin HJ; Chu YL; Chen YC; Tseng KC
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 1):58-65. PubMed ID: 33518448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world study of hepatitis C treatment with direct-acting antivirals in patients with drug abuse and opioid agonist therapy.
    Gayam V; Tiongson B; Mandal AK; Garlapati P; Pan C; Mohanty S
    Scand J Gastroenterol; 2019 May; 54(5):646-655. PubMed ID: 31120776
    [No Abstract]   [Full Text] [Related]  

  • 28. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Su F; Beste LA; Green PK; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection.
    Néant N; Solas C
    Int J Antimicrob Agents; 2020 Jul; 56(1):105571. PubMed ID: 30394302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort.
    Coghlan M; O'Leary A; Melanophy G; Bergin C; Norris S
    Int J Clin Pharm; 2019 Oct; 41(5):1227-1238. PubMed ID: 31297695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
    Garrison KL; German P; Mogalian E; Mathias A
    Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
    Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.
    Uriarte-Pinto M; Navarro-Aznarez H; De La Llama-Celis N; Arazo-Garcés P; Martínez-Sapiña AM; Abad-Sazatornil MR
    Int J Clin Pharm; 2018 Jun; 40(3):608-616. PubMed ID: 29556931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.
    Lanini S; Scognamiglio P; Mecozzi A; Lombardozzi L; Vullo V; Angelico M; Gasbarrini A; Taliani G; Attili AF; Perno CF; De Santis A; Puro V; Cerqua F; D'Offizi G; Pellicelli A; Armignacco O; Mennini FS; Siciliano M; Girardi E; Panella V; Ippolito G;
    BMC Infect Dis; 2018 May; 18(1):223. PubMed ID: 29769038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.